Eton Pharmaceuticals, Inc. (ETON)

Market Cap	119.80M
Revenue (ttm)	29.67M
Net Income (ttm)	-234,000
Shares Out	25.65M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	312.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,649
Open	4.53
Previous Close	4.64
Day's Range	4.45 - 4.67
52-Week Range	1.98 - 5.81
Beta	1.35
Analysts	Strong Buy
Price Target	10.00 (+114.13%)
Earnings Date	Nov 9, 2023

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydroco...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON

Financial Performance

In 2022, ETON's revenue was $22.89 million, a decrease of -1.89% compared to the previous year's $23.33 million. Losses were -$9.02 million, 361.4% more than in 2021.

Analyst Forecast

According to one analyst, the rating for ETON stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(114.13% upside)

Analyst Consensus: Strong Buy